Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma

Am J Clin Oncol. 2005 Oct;28(5):526. doi: 10.1097/01.coc.0000145982.86749.b4.

Abstract

Interferon (IFN)-alpha 2b is used for adjuvant therapy in malignant melanoma. Neurotoxicity as a side effect has been well described. Resting and action tremor related to interferon have been reported but are relatively uncommon. We report a case of a delayed-onset interferon-related action tremor in a patient with malignant melanoma.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects*
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Melanoma / drug therapy*
  • Recombinant Proteins
  • Severity of Illness Index
  • Skin Neoplasms / drug therapy*
  • Tremor / chemically induced*

Substances

  • Antineoplastic Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins